Medtronic stock gains focus as ablation registries support growth
Published on 11/03/2026 at 18:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCardiac Ablation Evidence Supports Focus
- Medtronic reported positive registry results for the Sphere-9 catheter and PulseSelect PFA System.
- The findings add clinical support to the cardiovascular portfolio after the MiniMed separation.
- Investors will focus next on adoption, procedure volumes and execution across the continuing businesses.
Medtronic reported positive real-world registry results for two cardiac ablation systems on Thursday, October 22, 2026. The company's press release said analyses from the Global APEX and REAL PULSE registries showed strong safety and procedural outcomes across atrial fibrillation and ventricular tachycardia.
The update covers the Sphere-9 catheter, used with the Affera Mapping and Ablation System, and the PulseSelect pulsed-field ablation system. It adds clinical evidence to Medtronic's cardiovascular portfolio as the company concentrates on cardiovascular, neuroscience and surgical businesses after completing the MiniMed separation.
Registry Results Add Clinical Support
The global APEX analysis included 1,050 atrial fibrillation patients treated across 28 sites. The reported major complication rate was 1.1%, with no acute kidney injury, severe coronary spasm or phrenic nerve injury.
The REAL PULSE registry included 1,160 atrial fibrillation patients across 38 sites. Medtronic reported a 100% acute success rate and an acute major complication rate of 0.09%.
A separate European APEX analysis covered 46 patients with sustained ventricular tachycardia. Acute success reached 87%, while estimated freedom from ventricular tachycardia recurrence at six months was 75%; six major complications occurred in four patients. Medtronic states that Sphere-9 is CE marked for ventricular tachycardia but remains investigational and not approved for that indication in the United States.
What Investors Watch Next
The registry findings do not change financial guidance. Their investor relevance lies in whether clinical adoption converts into procedure volumes, recurring revenue and stronger execution in cardiac ablation. The cardiovascular franchise therefore remains an important test of Medtronic's portfolio strategy after the diabetes technology exit.
Medtronic stock traded at 88.54 euros on Lang & Schwarz at 18:08 CET on Tuesday, November 3, 2026. Compared with the 86.97-euro quote in the October 30 report, the stock was 1.81% higher. The real-time quote of Medtronic stock is available here.
Medtronic plc at a Glance
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- NYSE ticker: MDT
- Lang & Schwarz quote: 88.54 euros at 18:08 CET on Tuesday, November 3, 2026
- Change versus October 30 report: 1.81% above 86.97 euros
The S&P 500 provides a broad US market backdrop for investors; see current market reports.
Further clinical adoption, product launches and portfolio execution will shape the next phase of the investment case. See more news and analyses on Medtronic stock.
